Base de dados : MEDLINE
Pesquisa : D12.776.543.750.705.852.760.072 [Categoria DeCS]
Referências encontradas : 2148 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 215 ir para página                         

  1 / 2148 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29308859
[Au] Autor:Radovic Janosevic D; Popovic J; Krstic M; Tubic-Pavlovic A; Stefanovic M; Pop-Trajkovic S
[Ti] Título:The structure of immunocompetent decidual cells in recurrent missed abortions.
[So] Source:Vojnosanit Pregl;73(4):306-11, 2016 Apr.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Background/Aim: Recurrent or habitual missed abortions (RMA) are defined as three or more consecutive abortions. In the first trimester of pregnancy habitual missed abortions occur in about 1% of population. The aim of this immunohistochemical study of decidua in RMA of unknown etiology was to identify subpopulations of decidual lymphocytes in recurrent miscarriages and compare the distribution of immunocompetent cells in artificial abortions and RMA. Methods. The study included 30 women with at least 2 consecutive miscarriages in the first trimester of pregnancy. Curettements of the third missed abortion were immunohistochemically analyzed. The control group consisted of 20 women without loaded reproductive anamnesis, with the abortion for social reasons. Criteria for exclusion from the study were diagnosed uterine anomalies, positive screening for thrombophilia and women who suffered from diabetes mellitus and disorders in the function of the thyroid gland. Immunophenotyping was performed by immuno-alkaline phosphatase (APAAP) using monoclonal antibodies: CD 30, CD 45 RO, CD 56 and CD 57, CD 68. Methods: The number of missed abortions (1,223) was on the average 9.7% of all deliveriies during the test period. Among them RMA were registered in 52 (4.2%) patients and in 30 (57%) the exact etiology of abortions was not determined. RMA was most common in the 25-34 years of age group. The largest number of RMA showed the ultrasound characteristics of missed abortion in 60% of cases and was in nulliparous patients (76.7%). The number of NK CD56 positive cells did not differ significantly between the types of abortion. In the decidual tissue, a number of NK CD57 positive cells was significantly higher in missed abortions compared to artificial interruptions (p < 0.01). In artificial termination of pregnancy there was an absolute predominance of CD45RO lymphocyte subpopulations, whereas in the RMA group there was slightly greater predominance of CD30 positive cells. The completed analysis showed a significantly higher number of CD68 positive macrophages in a decidual tissue of RMA pregnancy (p < 0.01). Results: The number and phenotypic structure of NK cells are significantly different in normal pregnancy decidua and in RMA. The NK cell dominance is present in the RMA group, in favor of CD56+ and CD 57 of subpopulations with increased CD30 of T lymphocyte subpopulations. Macrophages are more numerous in the decidua of pregnancies ended in abortion, so the cause to RMA of unknown etiology in a number of cases could be disregulation of immunocompetent cells.
[Mh] Termos MeSH primário: Aborto Retido/imunologia
Decídua/imunologia
Decídua/metabolismo
Células Matadoras Naturais/imunologia
[Mh] Termos MeSH secundário: Aborto Retido/metabolismo
Adulto
Antígeno CD56
Antígenos CD57
Feminino
Seres Humanos
Imuno-Histoquímica
Imunofenotipagem
Antígeno Ki-1
Células Matadoras Naturais/classificação
Células Matadoras Naturais/metabolismo
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CD56 Antigen); 0 (CD57 Antigens); 0 (Ki-1 Antigen); 0 (NCAM1 protein, human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE
[do] DOI:10.2298/VSP141226018R


  2 / 2148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29257929
[Au] Autor:Lezama LS; Gratzinger D
[Ad] Endereço:From the Department of Pathology, Mount Sinai St Luke's, Icahn School of Medicine at Mount Sinai, New York, New York (Dr Lezama); and the Department of Pathology, Stanford University School of Medicine, Stanford, California (Dr Gratzinger).
[Ti] Título:Nodal Involvement by CD30 Cutaneous Lymphoproliferative Disorders and Its Challenging Differentiation From Classical Hodgkin Lymphoma.
[So] Source:Arch Pathol Lab Med;142(1):139-142, 2018 Jan.
[Is] ISSN:1543-2165
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary cutaneous lymphomas are defined as non-Hodgkin lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. Mycosis fungoides is the most common type of primary cutaneous T-cell lymphoma, representing almost 50% of primary cutaneous T-cell lymphomas, and primary cutaneous CD30 T-cell lymphoproliferative disorders are the second most common group (30%). Transformed mycosis fungoides is usually CD30 and can involve multiple nodal sites; other primary cutaneous CD30 T-cell lymphoproliferative disorders can also involve draining regional nodes. Nodal involvement by CD30 T-cell lymphoproliferative disorders can mimic classical Hodgkin lymphoma, which can aberrantly express T-cell antigens. The aim of this article is to briefly review salient clinical, histologic, immunophenotypic, and molecular features that can be used to distinguish lymph node involvement by CD30 cutaneous T-cell lymphomas and lymphoproliferative disorders from classical Hodgkin lymphoma, a clinically important differential diagnosis that represents a challenging task for the pathologist.
[Mh] Termos MeSH primário: Doença de Hodgkin/diagnóstico
Transtornos Linfoproliferativos/diagnóstico
[Mh] Termos MeSH secundário: Linfócitos B/imunologia
Linfócitos B/patologia
Diagnóstico Diferencial
Citometria de Fluxo
Doença de Hodgkin/imunologia
Doença de Hodgkin/patologia
Seres Humanos
Imuno-Histoquímica
Antígeno Ki-1/metabolismo
Linfonodos/imunologia
Linfonodos/patologia
Linfoma Cutâneo de Células T/diagnóstico
Linfoma Cutâneo de Células T/imunologia
Transtornos Linfoproliferativos/imunologia
Transtornos Linfoproliferativos/patologia
Micose Fungoide/diagnóstico
Micose Fungoide/imunologia
Prognóstico
Linfócitos T/imunologia
Linfócitos T/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Ki-1 Antigen)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE
[do] DOI:10.5858/arpa.2016-0352-RS


  3 / 2148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28802087
[Au] Autor:Untanu RV; Back J; Appel B; Pei Q; Chen L; Buxton A; Hodgson DC; Ehrlich PF; Constine LS; Schwartz CL; Hutchison RE
[Ad] Endereço:Division of Clinical Pathology, Department of Pathology, State University of New York Upstate Medical University, Syracuse, New York.
[Ti] Título:Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL. PROCEDURE: One hundred sixty-eight cases of localized NLPHL were examined for histologic variants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored categorically as 0 = 0, 1 ≤ 25%, and 2 > 25% of the sample. RESULTS: Fifty-eight (35.1%) cases showed only typical nodular with or without serpiginous histology (types A and B). The remainder showed mixtures of histologies. The numbers of patients with score 2 are 85 (50.6%) type A, 21 (12.5%) type B, 46 (27.4%) with extranodular large B cells (type C), 3 with T-cell-rich nodular pattern (type D), 55 (32.7%) with diffuse T-cell-rich (type E) pattern, and 2 (1.2%) with diffuse B-cell pattern (type F). Higher level of types C (P = 0.048) and D (P = 0.033) resulted in lower event-free survival (EFS). Cytoplasmic IgD was found in 65 of 130 tested (50%), did not significantly associate with EFS but positively correlated with types C and E histology (P < 0.0001) and negatively correlated with types A (P = 0.0003) and B (P = 0.006). Seventeen (10%) expressed CD30, with no adverse effect. CONCLUSIONS: Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival.
[Mh] Termos MeSH primário: Linfócitos B
Regulação Neoplásica da Expressão Gênica
Doença de Hodgkin
Imunoglobulina D/biossíntese
Antígeno Ki-1/biossíntese
Linfócitos T
[Mh] Termos MeSH secundário: Adolescente
Linfócitos B/metabolismo
Linfócitos B/patologia
Criança
Pré-Escolar
Intervalo Livre de Doença
Feminino
Doença de Hodgkin/metabolismo
Doença de Hodgkin/mortalidade
Doença de Hodgkin/patologia
Seres Humanos
Imuno-Histoquímica
Lactente
Recém-Nascido
Masculino
Taxa de Sobrevida
Linfócitos T/metabolismo
Linfócitos T/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Immunoglobulin D); 0 (Ki-1 Antigen)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180101
[Lr] Data última revisão:
180101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170813
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26753


  4 / 2148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28805662
[Au] Autor:Ramos CA; Ballard B; Zhang H; Dakhova O; Gee AP; Mei Z; Bilgi M; Wu MF; Liu H; Grilley B; Bollard CM; Chang BH; Rooney CM; Brenner MK; Heslop HE; Dotti G; Savoldo B
[Ad] Endereço:Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, Texas, USA.
[Ti] Título:Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
[So] Source:J Clin Invest;127(9):3462-3471, 2017 Sep 01.
[Is] ISSN:1558-8238
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS: We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being treated with brentuximab. RESULTS: No toxicities attributable to CD30.CAR-Ts were observed. Of 7 patients with relapsed HL, 1 entered complete response (CR) lasting more than 2.5 years after the second infusion of CD30.CAR-Ts, 1 remained in continued CR for almost 2 years, and 3 had transient stable disease. Of 2 patients with ALCL, 1 had a CR that persisted 9 months after the fourth infusion of CD30.CAR-Ts. CD30.CAR-T expansion in peripheral blood peaked 1 week after infusion, and CD30.CAR-Ts remained detectable for over 6 weeks. Although CD30 may also be expressed by normal activated T cells, no patients developed impaired virus-specific immunity. CONCLUSION: CD30.CAR-Ts are safe and can lead to clinical responses in patients with HL and ALCL, indicating that further assessment of this therapy is warranted. TRIAL REGISTRATION: ClinicalTrials.gov NCT01316146. FUNDING: National Cancer Institute (3P50CA126752, R01CA131027 and P30CA125123), National Heart, Lung, and Blood Institute (R01HL114564), and Leukemia and Lymphoma Society (LLSTR 6227-08).
[Mh] Termos MeSH primário: Doença de Hodgkin/terapia
Antígeno Ki-1/metabolismo
Linfoma Anaplásico de Células Grandes/terapia
Receptores de Antígenos de Linfócitos T/química
Linfócitos T/citologia
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/química
Antígenos CD28/química
Progressão da Doença
Relação Dose-Resposta a Droga
Feminino
Doença de Hodgkin/imunologia
Seres Humanos
Imunoconjugados/administração & dosagem
Imunoconjugados/uso terapêutico
Imunofenotipagem
Linfoma Anaplásico de Células Grandes/imunologia
Masculino
Meia-Idade
Terapia de Alvo Molecular
Recidiva Local de Neoplasia
Condicionamento Pré-Transplante
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (CD28 Antigens); 0 (Immunoconjugates); 0 (Ki-1 Antigen); 0 (Receptors, Antigen, T-Cell); 7XL5ISS668 (brentuximab vedotin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE


  5 / 2148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28715445
[Au] Autor:Di Napoli A; Pepe G; Giarnieri E; Cippitelli C; Bonifacino A; Mattei M; Martelli M; Falasca C; Cox MC; Santino I; Giovagnoli MR
[Ad] Endereço:Department of Clinical and Molecular Medicine, Sapienza University, Pathology Unit, Sant'Andrea Hospital, Roma, Italy.
[Ti] Título:Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma.
[So] Source:PLoS One;12(7):e0181097, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Late breast implant seroma may be the presentation of a breast implant-associated anaplastic large cell lymphoma (BI-ALCL), which claims for a prompt recognition. However, BI-ALCL diagnosis on fine-needle aspiration (FNA) might be challenging for pathologists lacking experience with peri-implant breast effusions. Sixty-seven late breast implant seromas collected by FNA from 50 patients were evaluated by Papanicolaou smear stain and immunocytochemistry on cell blocks. A diagnostic algorithm based on the cellular composition, cell morphology and percentage of CD30+ cells was developed. Histological evaluation of the corresponding peri-prosthetic capsules was also performed. Most of the effusions (91% of the samples) were classified as reactive and 9% as BI-ALCL. In the BI-ALCL cases, medium-to-large atypical cells expressing CD30 represented more than 70% of the cellularity, whereas in in the reactive effusions CD30+ elements were extremely rare (<5%) and consisted of non-atypical elements. The reactive effusions were categorized into three patterns: i) acute infiltrate with prominent neutrophilic component (33% of the samples); ii) mixed infiltrate characterized by a variable number of neutrophils, lymphocytes and macrophages (30% of the samples); iii) chronic infiltrate composed predominantly of T lymphocytes or macrophages with only sporadic granulocytes (37% of the samples). The inflammatory cytological patterns were consistent with the histology of the corresponding capsules. Our results indicate that cytological analysis of late breast implant effusions, supported by the knowledge of the heterogeneous cytomorphological spectrum of late seromas, is a valuable approach for the early recognition of BI-ALCL.
[Mh] Termos MeSH primário: Implante Mamário
Neoplasias da Mama/patologia
Linfoma Anaplásico de Células Grandes/patologia
Seroma/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antígenos CD/metabolismo
Antígenos de Diferenciação Mielomonocítica/metabolismo
Complexo CD3/metabolismo
Feminino
Rearranjo Gênico
Seres Humanos
Antígeno Ki-1/metabolismo
Klebsiella oxytoca/isolamento & purificação
Linfócitos/citologia
Linfócitos/metabolismo
Macrófagos/citologia
Macrófagos/metabolismo
Meia-Idade
Neutrófilos/citologia
Neutrófilos/metabolismo
Pseudomonas aeruginosa/isolamento & purificação
Receptores de Antígenos de Linfócitos T gama-delta/genética
Receptores de Antígenos de Linfócitos T gama-delta/metabolismo
Seroma/microbiologia
Serratia marcescens/isolamento & purificação
Staphylococcus aureus/isolamento & purificação
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD); 0 (Antigens, Differentiation, Myelomonocytic); 0 (CD3 Complex); 0 (CD68 antigen, human); 0 (Ki-1 Antigen); 0 (Receptors, Antigen, T-Cell, gamma-delta)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170718
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181097


  6 / 2148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28665214
[Au] Autor:Eichenauer DA; Engert A
[Ad] Endereço:a First Department of Internal Medicine , University Hospital Cologne , Cologne , Germany.
[Ti] Título:The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.
[So] Source:Expert Rev Hematol;10(9):775-782, 2017 Sep.
[Is] ISSN:1747-4094
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Hodgkin lymphoma (HL) is a B-cell-derived malignancy mostly affecting young adults. More than 80% of patients are cured after stage-adapted first-line treatment with chemotherapy and/or radiotherapy. About 50% of patients with disease recurrence achieve long-term remission with second-line treatment consisting of high-dose chemotherapy and autologous stem cell transplantation. However, HL treatment is often associated with acute toxicity and in part life-threatening late effects. Implementing targeted drugs may reduce toxicity and potentially further optimize efficacy. In recent years, the CD30-directed antibody-drug conjugate brentuximab vedotin (BV) and anti-PD-1 antibodies, nivolumab and pembrolizumab, underwent extensive evaluation in HL. They have exhibited encouraging single agent activity and a favorable toxicity profile in patients with multiple relapses. Therefore, they are currently under investigation in different additional indications. Areas covered: This article gives an overview over clinical trials evaluating targeted drugs either as single agent or as part of combination therapies in HL patients. Expert commentary: A multitude of targeted drugs are investigated in HL. Promising data have particularly emerged from studies with BV and anti-PD-1 antibodies. However, mature data needed for final conclusions are still pending.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Doença de Hodgkin/tratamento farmacológico
Terapia de Alvo Molecular
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/uso terapêutico
Anticorpos Monoclonais Humanizados/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Ensaios Clínicos como Assunto
Descoberta de Drogas
Inibidores de Histona Desacetilases/uso terapêutico
Doença de Hodgkin/mortalidade
Doença de Hodgkin/patologia
Seres Humanos
Imunoconjugados/uso terapêutico
Antígeno Ki-1/antagonistas & inibidores
Recidiva
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (Antineoplastic Agents); 0 (Histone Deacetylase Inhibitors); 0 (Immunoconjugates); 0 (Ki-1 Antigen); 31YO63LBSN (nivolumab); 7XL5ISS668 (brentuximab vedotin); DPT0O3T46P (pembrolizumab)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170701
[St] Status:MEDLINE
[do] DOI:10.1080/17474086.2017.1350167


  7 / 2148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28473406
[Au] Autor:Chen YB; Perales MA; Li S; Kempner M; Reynolds C; Brown J; Efebera YA; Devine SM; El-Jawahri A; McAfee SL; Spitzer TR; Soiffer RJ; Ritz J; Cutler C
[Ad] Endereço:Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA.
[Ti] Título:Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease.
[So] Source:Blood;129(24):3256-3261, 2017 Jun 15.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains suboptimal. Preclinical data demonstrate increased CD30 expression on activated CD8 T cells during aGVHD. Brentuximab vedotin (BV) is an antibody-drug conjugate targeting CD30. We conducted a multicenter phase 1 trial in 34 patients to establish the maximum tolerated dose (MTD) of BV for SR-aGVHD treatment. A 3+3 cohort design was conducted initially with BV given weekly × 3 doses followed by maintenance dosing (initial dose 0.6 mg/kg IV weekly). Six patients were treated with the initial weekly dosing scheme; 2 of these patients died of neutropenic sepsis complications. The trial was subsequently revised to escalating cohorts of 5 patients treated every 2 weeks × 4 doses with a 4-week dose-limiting toxicity (DLT) period. Twenty-eight patients were treated with every-2-week dosing (n = 10 at 0.6 mg/kg; n = 18 at 0.8 mg/kg). MTD was defined at 0.8 mg/kg with 1 DLT observed (sepsis). At day 28, the overall response rate was 38.2% with 5 complete responses (CRs; 14.7%) and 8 very-good-partial responses (23.5%). An additional 7 patients achieved CR by day 56. With 12 months' follow-up on all patients, overall survival was 41% (95% confidence interval [CI], 25%-57%) at 6 months and 38% (95% CI, 22%-54%) at 12 months. CD30 expression on central memory CD8 , central memory CD4 , and regulatory T-lymphocyte subsets at enrollment was not associated with clinical response. BV is tolerable and has activity in SR-aGVHD and merits further investigation. This trial was registered at www.clinicaltrials.gov as #NCT01940796.
[Mh] Termos MeSH primário: Doença Enxerto-Hospedeiro/tratamento farmacológico
Imunoconjugados/administração & dosagem
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Assistência ao Convalescente
Idoso
Aloenxertos
Linfócitos T CD8-Positivos/imunologia
Linfócitos T CD8-Positivos/patologia
Feminino
Doença Enxerto-Hospedeiro/imunologia
Doença Enxerto-Hospedeiro/patologia
Transplante de Células-Tronco Hematopoéticas
Seres Humanos
Imunoconjugados/efeitos adversos
Antígeno Ki-1/imunologia
Masculino
Dose Máxima Tolerável
Meia-Idade
Neoplasias/imunologia
Neoplasias/terapia
Linfócitos T Reguladores/imunologia
Linfócitos T Reguladores/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Immunoconjugates); 0 (Ki-1 Antigen); 7XL5ISS668 (brentuximab vedotin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170506
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2017-03-772210


  8 / 2148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28427526
[Au] Autor:Berger GK; Gee K; Votruba C; McBride A; Anwer F
[Ad] Endereço:College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States; Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States. Electronic address: garrettkberger@gmail.com.
[Ti] Título:Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature.
[So] Source:Crit Rev Oncol Hematol;113:8-17, 2017 May.
[Is] ISSN:1879-0461
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: CD30 (Ki-1) is a cell membrane protein derived from the tumor necrosis factor (TNF) receptor family. The CD30 antigen has been associated primarily with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Brentuximab vedotin (BV) is an antibody-drug conjugate targeting the CD30 antigen. FDA approval for BV includes relapsed and refractory HL and sALCL. The CD30 antigen also has been identified in many solid tumors, predominantly of germ cell origins and early clinical data is promising. OBJECTIVE: Perform a focus literature review evaluating the prevalence of the CD30 antigen among nonlymphomatous tumors with a potential correlate for CD30 targeted therapy. ELIGIBILITY CRITERIA: Inclusion criteria: all retrospective reviews and case reports citing CD30 positivity or negativity in non-lymphomatous malignancies in which data were presented based on location. EXCLUSION CRITERIA: studies with hematopoetic malignancies, cutaneous malignancies, non-human populations, and non-english publications. INCLUDED STUDIES: A total of 119 articles met these criteria and are summarized in this manuscript. CONCLUSION: The CD30 antigen has shown variable prevalence among non-hematopoetic tumors, most notably among germ cell tumors and mesothelioma. With additional, preclinical and properly powered clinical studies, CD30 targeted therapy such as that of BV, alone or in combination with other agents may prove to be a strong candidate in the treatment of various CD30 malignancies.
[Mh] Termos MeSH primário: Antígeno Ki-1/imunologia
Neoplasias/metabolismo
[Mh] Termos MeSH secundário: Antineoplásicos/uso terapêutico
Seres Humanos
Imunoconjugados/uso terapêutico
Imunoterapia
Neoplasias/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Immunoconjugates); 0 (Ki-1 Antigen); 7XL5ISS668 (brentuximab vedotin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE


  9 / 2148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28348271
[Au] Autor:Mokada-Gopal L; Boeser A; Lehmann CHK; Drepper F; Dudziak D; Warscheid B; Voehringer D
[Ad] Endereço:Department of Infection Biology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.
[Ti] Título:Identification of Novel STAT6-Regulated Proteins in Mouse B Cells by Comparative Transcriptome and Proteome Analysis.
[So] Source:J Immunol;198(9):3737-3745, 2017 May 01.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The transcription factor STAT6 plays a key role in mediating signaling downstream of the receptors for IL-4 and IL-13. In B cells, STAT6 is required for class switch recombination to IgE and for germinal center formation during type 2 immune responses directed against allergens or helminths. In this study, we compared the transcriptomes and proteomes of primary mouse B cells from wild-type and STAT6-deficient mice cultured for 4 d in the presence or absence of IL-4. Microarray analysis revealed that 214 mRNAs were upregulated and 149 were downregulated >3-fold by IL-4 in a STAT6-dependent manner. Across all samples, ∼5000 proteins were identified by label-free quantitative liquid chromatography/mass spectrometry. A total of 149 proteins was found to be differentially expressed >3-fold between IL-4-stimulated wild-type and STAT6 B cells (75 upregulated and 74 downregulated). Comparative analysis of the proteome and transcriptome revealed that expression of these proteins was mainly regulated at the transcriptional level, which argues against a major role for posttranscriptional mechanisms that modulate the STAT6-dependent proteome. Nine proteins were selected for confirmation by flow cytometry or Western blot. We show that CD30, CD79b, SLP-76, DEC205, IL-5Rα, STAT5, and Thy1 are induced by IL-4 in a STAT6-dependent manner. In contrast, Syk and Fc receptor-like 1 were downregulated. This dataset provides a framework for further functional analysis of newly identified IL-4-regulated proteins in B cells that may contribute to germinal center formation and IgE switching in type 2 immunity.
[Mh] Termos MeSH primário: Linfócitos B/imunologia
Interleucina-4/imunologia
Proteoma
Fator de Transcrição STAT6/metabolismo
Transcriptoma
[Mh] Termos MeSH secundário: Proteínas Adaptadoras de Transdução de Sinal/genética
Proteínas Adaptadoras de Transdução de Sinal/metabolismo
Animais
Antígenos CD79/genética
Antígenos CD79/metabolismo
Diferenciação Celular
Células Cultivadas
Regulação da Expressão Gênica/genética
Regulação da Expressão Gênica/imunologia
Switching de Imunoglobulina/genética
Imunoglobulina E/metabolismo
Antígeno Ki-1/genética
Antígeno Ki-1/metabolismo
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Knockout
Fosfoproteínas/genética
Fosfoproteínas/metabolismo
Fator de Transcrição STAT6/genética
Fator de Transcrição STAT6/imunologia
Células Th2/imunologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adaptor Proteins, Signal Transducing); 0 (CD79 Antigens); 0 (Ki-1 Antigen); 0 (Phosphoproteins); 0 (Proteome); 0 (SLP-76 signal Transducing adaptor proteins); 0 (STAT6 Transcription Factor); 0 (STAT6 protein, human); 207137-56-2 (Interleukin-4); 37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170329
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1601838


  10 / 2148 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28190142
[Au] Autor:Scott LJ
[Ad] Endereço:Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
[Ti] Título:Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
[So] Source:Drugs;77(4):435-445, 2017 Mar.
[Is] ISSN:1179-1950
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Intravenous brentuximab vedotin (ADCETRIS ) is a targeted antibody-drug conjugate (ADC) active against CD30-positive cancer cells such as those associated with classical Hodgkin lymphoma (HL). In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin resulted in high objective response (complete plus partial remission) rates in patients with relapsed or refractory CD30-positive HL, including as retreatment in patients who had an objective response to previous brentuximab vedotin therapy and subsequently relapsed. These beneficial outcomes were durable during long-term follow-up. As consolidation therapy after autologous haematopoietic stem cell transplant (ASCT) in the multinational, phase 3 AETHERA trial, brentuximab vedotin prolonged progression-free-survival (PFS) compared with placebo at a median follow-up of 30 months (primary analysis), with a 43% reduction in the risk of disease progression or death. The beneficial effects of brentuximab vedotin consolidation therapy were maintained during long-term follow-up. In the clinical trial and real-world setting, brentuximab vedotin had an acceptable tolerability and safety profile, with most adverse events manageable with dose reductions and/or delays [including peripheral sensory neuropathy (PSN) and neutropenia]. With a paucity of treatments available for many patients with relapsed or refractory HL, brentuximab vedotin represents an important option for the management of patients who have failed high-dose chemotherapy/ASCT or at least two prior chemotherapy regimens and as post-ASCT consolidation therapy in patients who are at increased risk/high-risk of relapse or progression after ASCT.
[Mh] Termos MeSH primário: Imunoconjugados/uso terapêutico
Antígeno Ki-1/imunologia
Linfoma não Hodgkin/tratamento farmacológico
[Mh] Termos MeSH secundário: Tolerância a Medicamentos
Seres Humanos
Imunoconjugados/administração & dosagem
Linfoma não Hodgkin/imunologia
Terapia de Salvação
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Immunoconjugates); 0 (Ki-1 Antigen); 7XL5ISS668 (brentuximab vedotin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170213
[St] Status:MEDLINE
[do] DOI:10.1007/s40265-017-0705-5



página 1 de 215 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde